AR032465A1 - Derivados anticonvulsivos utiles para la preparacion de un medicamento para prevenir el desarrollo de la diabetes mellitus de tipo ii y del sindrome x - Google Patents

Derivados anticonvulsivos utiles para la preparacion de un medicamento para prevenir el desarrollo de la diabetes mellitus de tipo ii y del sindrome x

Info

Publication number
AR032465A1
AR032465A1 ARP010103263A ARP010103263A AR032465A1 AR 032465 A1 AR032465 A1 AR 032465A1 AR P010103263 A ARP010103263 A AR P010103263A AR P010103263 A ARP010103263 A AR P010103263A AR 032465 A1 AR032465 A1 AR 032465A1
Authority
AR
Argentina
Prior art keywords
syndrome
development
preparation
prevent
type
Prior art date
Application number
ARP010103263A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR032465A1 publication Critical patent/AR032465A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de sulfamatos de formula (1) en donde X es CH2 u oxígeno; R1 es hidrogeno o alquilo; y R2, R3, R4 y R5 son independientemente hidrogeno o alquilo inferior, y cuando X es CH2, R4 y R5 pueden ser grupos alqueno unidos entre sí para formar un anillo de benceno, y, cuando X es oxígeno, R2 y R3 y/o R4 y R5 juntos pueden ser un grupo metilendioxi de la formula (2): en donde R6 y R7 son iguales o diferentes y son hidrogeno, alquilo inferior o son alquilo y están unidos para formar un anillo ciclopentilo o ciclohexilo, para la preparacion de medicamentos para tratar o prevenir el desarrollo de diabetes mellitus de Tipo II y Síndrome X.
ARP010103263A 2000-07-07 2001-07-10 Derivados anticonvulsivos utiles para la preparacion de un medicamento para prevenir el desarrollo de la diabetes mellitus de tipo ii y del sindrome x AR032465A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21714100P 2000-07-07 2000-07-07
US27002201P 2001-02-20 2001-02-20

Publications (1)

Publication Number Publication Date
AR032465A1 true AR032465A1 (es) 2003-11-12

Family

ID=26911655

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103263A AR032465A1 (es) 2000-07-07 2001-07-10 Derivados anticonvulsivos utiles para la preparacion de un medicamento para prevenir el desarrollo de la diabetes mellitus de tipo ii y del sindrome x

Country Status (22)

Country Link
US (2) US6852701B2 (es)
EP (1) EP1309324B1 (es)
JP (1) JP4920163B2 (es)
CN (1) CN101404993A (es)
AR (1) AR032465A1 (es)
AT (1) ATE320805T1 (es)
AU (1) AU2001280486A1 (es)
BR (1) BR0112519A (es)
CA (1) CA2415093A1 (es)
DE (1) DE60118206T2 (es)
DK (1) DK1309324T3 (es)
ES (1) ES2260261T3 (es)
HU (1) HUP0302307A3 (es)
IL (1) IL153713A0 (es)
MX (1) MXPA03000136A (es)
MY (1) MY126897A (es)
NO (1) NO20030064L (es)
NZ (1) NZ523531A (es)
PL (1) PL365680A1 (es)
PT (1) PT1309324E (es)
RU (1) RU2268720C2 (es)
WO (1) WO2002003984A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
AU2003297639A1 (en) * 2002-12-02 2004-06-23 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY142329A (en) * 2004-08-24 2010-11-15 Janssen Pharmaceutica Nv Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
KR20080012360A (ko) * 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
AU2007319141B2 (en) 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
MX2009003911A (es) * 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
NO2106260T3 (es) * 2007-01-25 2018-05-05
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN104220064B (zh) 2012-03-23 2017-10-10 中国人民解放军军事医学科学院毒物药物研究所 一种含辛弗林和托吡酯的联合产品
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
CA2258893C (en) * 1996-06-28 2005-06-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
AU779248B2 (en) 1999-02-24 2005-01-13 University Of Cincinnati, The Use of sulfamate derivatives for treating impulse control disorders
JP2003530300A (ja) 1999-04-08 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 体重低下を維持することに有用な抗痙攣薬誘導体
NZ514811A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
JP2002541199A (ja) * 1999-04-08 2002-12-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 脂質を下げることに有用な抗痙攣薬誘導体
CA2686633A1 (en) * 1999-06-14 2000-12-21 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity

Also Published As

Publication number Publication date
ATE320805T1 (de) 2006-04-15
CA2415093A1 (en) 2002-01-17
AU2001280486A1 (en) 2002-01-21
JP4920163B2 (ja) 2012-04-18
NO20030064L (no) 2003-03-06
CN101404993A (zh) 2009-04-08
IL153713A0 (en) 2003-07-06
JP2004510700A (ja) 2004-04-08
DK1309324T3 (da) 2006-06-12
HUP0302307A2 (hu) 2003-10-28
MXPA03000136A (es) 2004-09-13
PL365680A1 (en) 2005-01-10
EP1309324B1 (en) 2006-03-22
WO2002003984A3 (en) 2003-03-06
ES2260261T3 (es) 2006-11-01
EP1309324A2 (en) 2003-05-14
DE60118206T2 (de) 2006-12-14
NZ523531A (en) 2005-07-29
MY126897A (en) 2006-10-31
US6852701B2 (en) 2005-02-08
NO20030064D0 (no) 2003-01-06
US20020037861A1 (en) 2002-03-28
RU2268720C2 (ru) 2006-01-27
PT1309324E (pt) 2006-06-30
BR0112519A (pt) 2004-03-30
WO2002003984A2 (en) 2002-01-17
HUP0302307A3 (en) 2007-05-29
US7109174B2 (en) 2006-09-19
US20040209824A1 (en) 2004-10-21
DE60118206D1 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
AR032465A1 (es) Derivados anticonvulsivos utiles para la preparacion de un medicamento para prevenir el desarrollo de la diabetes mellitus de tipo ii y del sindrome x
CA2369099A1 (en) Anticonvulsant derivatives useful in reducing blood glucose levels
ES422395A1 (es) Un procedimiento para la preparacion de cinamamidas e hi- drocinamamidas.
CA2369093A1 (en) Anticonvulsant derivatives useful in lowering lipids
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
CA2369095A1 (en) Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
HUP0105154A2 (hu) Cluster típusú fejfájás kezelésére alkalmas görcsoldószármazékok
ES2174989T3 (es) Pirido(3,2-e)pirazinonas con antiasmatica y procedimiento para su preparacion.
FI860842A (fi) Labdan-derivat, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
AR029334A1 (es) Uso de derivados anti-convulsivos para la manufactura de un medicamento para el tratamiento del autismo
AR029331A1 (es) Uso de derivados anticonvulsivos para la manufactura de un medicamento en el tratamiento de la bulimia nerviosa
AR008543A1 (es) Un compuesto de camptotecina, un medicamento, una composicion farmaceutica que lo comprende y el uso del compuesto.
AR034088A1 (es) Composicion que comprende derivados anticonvulsivantes utiles en el tratamiento de esquizofrenia y el uso de dicho derivado para la manufactura de un medicamento
BR0115119A (pt) Derivados tricìclicos de indol com atividade antiangiogênica
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
AR035594A1 (es) Uso de sulfamatos para la preparacion de medicamentos
NZ333587A (en) Topiramate derivatives useful in treating psoriasis
DK0418064T3 (da) Naphthalen- og tetrahydronaphthalen-substituerede gem-diphosphonatderivater
DE3678645D1 (de) Neue thieno-1,2-thiazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
AR035005A1 (es) Composicion para el tratamiento del trastorno por estres post traumatico
TR200000154T2 (tr) 2,4,4-Trisübstitüe-1,3-Dioksolan mantar önleyiciler.
IL95275A0 (en) Oxadiazolyl-phenoxyalkylisoxazoles,their preparation and pharmaceutical compositions containing them
NZ513724A (en) Anticonvulsant derivatives useful in treating essential tremor
ES2032838T3 (es) Un procedimiento para preparar derivados tetrahidropirido (1,2-a)indol.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal